Original Article
ISSN (Online): 2582-7472

ShodhKosh: Journal of Visual and Performing Arts
July 2024 5(7SE), 112–115

INVESTIGATING THE IMPACT OF COVID-19 ON LOSS OF SMELL (ANOSMIA) AND TASTE (AGEUSIA): A COMPREHENSIVE REVIEW

Jyoti Bala [1], Dr. Sanjay Sharma [2]

[1] Research Scholar, Department of Physical Education, Himachal Pradesh University, Shimla-5, India
[2] Professor Department of Physical Education, Himachal Pradesh University, Shimla-5, India

https://crossmark.crossref.org/dialog/?doi=10.29121/shodhkosh.v5.i7se.2024.5856&domain=pdf&date_stamp=2024-07-31

Corresponding Author

Jyoti Bala, jyotigupta2611p@gmail.com

DOI
10.29121/shodhkosh.v5.i7SE.2024.5856

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ABSTRACT

The loss of smell (anosmia) and taste (ageusia) has emerged as a distinctive symptom associated with COVID-19 infection. This paper provides an extensive review of existing literature on the prevalence, mechanisms, clinical implications, and management of anosmia and ageusia in COVID-19 patients. The sudden onset of these sensory deficits has significant implications for diagnosis, patient management, and public health strategies. By synthesizing findings from epidemiological studies, clinical reports, and mechanistic investigations, this review aims to deepen our understanding of the pathophysiology underlying COVID-19-related anosmia and ageusia and inform strategies for diagnosis, treatment, and prevention.

Keywords: COVID-19, Loss of Smell, Loss of Taste, Anosmia, Ageusia

1. INTRODUCTION

The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has introduced a wide array of symptoms, ranging from mild respiratory issues to severe respiratory distress and multi-organ dysfunction. Among the notable symptoms linked to COVID-19 are the sudden onset of anosmia (loss of smell) and ageusia (loss of taste). These sensory impairments have gained significant attention due to their prevalence among COVID-19 patients, prompting concerns regarding their diagnostic reliability, clinical implications, and underlying mechanisms. Nevertheless, despite differences in reported rates, anosmia and ageusia remain widely acknowledged as common symptoms of COVID-19.

Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. European Archives of Oto-Rhino-Laryngology, 1-11. Their sudden onset, particularly when accompanied by other symptoms such as fever or cough, can raise suspicion for COVID-19 infection and prompt individuals to seek testing and medical care. Furthermore, anosmia and ageusia may persist beyond the resolution of other symptoms, potentially serving as indicators for monitoring disease progression or recovery.

The mechanisms underlying anosmia and ageusia in COVID-19 are not fully elucidated but are believed to involve viral invasion of the olfactory and gustatory systems. SARS-CoV-2 gains entry into cells through the angiotensin-converting enzyme 2 (ACE2) receptor, which is expressed in cells of the nasal epithelium and oral mucosa. Viral infection and subsequent inflammation may disrupt normal olfactory and gustatory function, leading to anosmia and ageusia.

Inflammatory responses and immune-mediated mechanisms may also contribute to sensory deficits in COVID-19. Studies have reported evidence of inflammatory changes in the olfactory epithelium and alterations in cytokine levels in COVID-19 patients with anosmia or ageusia. Additionally, interactions between SARS-CoV-2 and the central nervous system may influence sensory perception.

Understanding the mechanisms underlying anosmia and ageusia in COVID-19 is crucial for developing targeted therapies and interventions to alleviate these symptoms and potentially improve patient outcomes. Moreover, ongoing research into the clinical implications and diagnostic utility of anosmia and ageusia in COVID-19 is essential for refining diagnostic criteria and optimizing management strategies for affected individuals.

2. PREVALENCE OF ANOSMIA AND AGEUSIA IN COVID-19

Numerous studies have documented a notable occurrence of anosmia and ageusia among individuals with COVID-19, with prevalence rates ranging between 30% to 80% (Gane et al., 2020; Klopfenstein et al., 2020; Lechien et al., 2020). These sensory impairments frequently manifest early in the illness and can sometimes be the sole presenting symptoms. Anosmia and ageusia have been noted in COVID-19 patients across various age demographics and disease severities, implying their potential as valuable markers for identifying COVID-19 infection.

3. MECHANISMS OF ANOSMIA AND AGEUSIA IN COVID-19

The exact mechanisms responsible for anosmia and ageusia in COVID-19 remain incompletely elucidated, but several potential pathways have been suggested. One proposed mechanism involves the direct invasion of the olfactory epithelium and taste buds by the virus, which can lead to the impairment or dysfunction of sensory neurons. Another possible mechanism is immune-mediated inflammation and the subsequent release of cytokines, which may result in neuronal injury and the disruption of sensory processing.

4. CLINICAL IMPLICATIONS OF ANOSMIA AND AGEUSIA

The sudden onset of anosmia and ageusia in COVID-19 patients has significant clinical implications, including challenges in early diagnosis, patient management, and infection control. These sensory deficits may complicate the recognition of COVID-19 cases, particularly in individuals with mild or atypical symptoms. Furthermore, anosmia and ageusia can have a profound impact on patients' quality of life, affecting their ability to enjoy food, detect hazards such as spoiled food or gas leaks, and maintain social connections.

5. MANAGEMENT OF ANOSMIA AND AGEUSIA IN COVID-19

There is currently no specific treatment for anosmia and ageusia associated with COVID-19. Management strategies focus on supportive care, including symptomatic relief, nutritional support, and psychosocial interventions. Olfactory training, consisting of repeated exposure to odorants, has shown promise in promoting recovery of olfactory function in some COVID-19 patients. However, further research is needed to determine the effectiveness of these interventions and their optimal timing and duration.

6. CONCLUSION

The loss of smell and taste has emerged as a distinctive symptom of COVID-19 infection, with significant implications for diagnosis, patient management, and public health strategies. By deepening our understanding of the mechanisms underlying anosmia and ageusia in COVID-19, this review provides valuable insights into the pathophysiology of the disease and informs strategies for diagnosis, treatment, and prevention. Further research is needed to elucidate the precise mechanisms of anosmia and ageusia in COVID-19 and develop targeted interventions to alleviate these sensory deficits and improve patients' quality of life.

The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has presented a myriad of symptoms, ranging from mild respiratory issues to severe respiratory distress and multi-organ dysfunction. Among the notable and distinctive symptoms associated with COVID-19 are the sudden onset of anosmia (loss of smell) and ageusia (loss of taste). These sensory deficits have garnered significant attention due to their prevalence among COVID-19 patients, raising concerns about their diagnostic utility, clinical implications, and underlying mechanisms.

Anosmia and ageusia have emerged as hallmark symptoms of COVID-19, often appearing early in the course of the disease or even as the initial presenting symptoms. Studies have indicated that a significant proportion of COVID-19 patients experience anosmia and ageusia, sometimes even in the absence of other typical respiratory symptoms like cough or fever.

The prevalence of anosmia and ageusia varies across different studies and populations. Some reports suggest that up to 60-80% of COVID-19 patients may experience alterations in smell or taste, while other studies suggest a lower prevalence. However, despite variations in reported prevalence rates, anosmia and ageusia remain recognized as common symptoms of COVID-19(Lechien et al., 2020).

These sensory deficits have implications for both diagnosis and management of COVID-19. Their sudden onset, especially when coupled with other symptoms such as fever or cough, can raise suspicion for COVID-19 infection and prompt individuals to seek testing and medical attention. Furthermore, anosmia and ageusia can persist beyond the resolution of other symptoms, potentially serving as markers for monitoring disease progression or recovery.

The underlying mechanisms of anosmia and ageusia in COVID-19 are not fully understood but are thought to involve viral invasion of the olfactory and gustatory systems. SARS-CoV-2 has been shown to gain entry into cells through the angiotensin-converting enzyme 2 (ACE2) receptor, which is expressed in cells of the nasal epithelium and the oral mucosa. Viral infection and subsequent inflammation may disrupt normal olfactory and gustatory function, leading to anosmia and ageusia.

In addition to direct viral effects, inflammatory responses and immune-mediated mechanisms may contribute to sensory deficits in COVID-19. Studies have reported evidence of inflammatory changes in the olfactory epithelium and alterations in cytokine levels in COVID-19 patients with anosmia or ageusia. Furthermore, there may be interactions between SARS-CoV-2 and the central nervous system, influencing sensory perception.

Understanding the mechanisms underlying anosmia and ageusia in COVID-19 is crucial for developing targeted therapies and interventions to alleviate these symptoms and potentially improve patient outcomes. Moreover, continued research into the clinical implications and diagnostic utility of anosmia and ageusia in COVID-19 is essential for refining diagnostic criteria and optimizing management strategies in affected individuals.

CONFLICT OF INTERESTS

None.

ACKNOWLEDGMENTS

None.

REFERENCES

Lechien, J. R., Chiesa-Estomba, C. M., De Siati, D. R., Horoi, M., Le Bon, S. D., Rodriguez, A., ... &Dequanter, D. (2020). Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. European Archives of Oto-Rhino-Laryngology, 1-11.

Vaira, L. A., Salzano, G., Deiana, G., De Riu, G., & Anosmia Study Group. (2020). Anosmia and ageusia: common findings in COVID-19 patients. The Laryngoscope, 130(7), 1787.

Brann, D. H., Tsukahara, T., Weinreb, C., Lipovsek, M., Van den Berge, K., Gong, B., ... &Datta, S. R. (2020). Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying anosmia in COVID-19 patients. bioRxiv.

Gane, S. B., Kelly, C., & Hopkins, C. (2020). Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome? Rhinology, 58(3), 299-301.

Klopfenstein, T., Kadiane-Oussou, N. J., Toko, L., Royer, P. Y., Lepiller, Q., Gendrin, V., ... &Zayet, S. (2020). Features of anosmia in COVID-19. Med Mal Infect, 50(5), 436-439.

Butowt, R., &Bilinska, K. (2020). SARS-CoV-2: Olfaction, Brain Infection, and the Urgent Need for Clinical Samples Allowing Earlier Virus Detection.ACS Chemical Neuroscience, 11(9), 1200–1203. https://doi.org/10.1021/acschemneuro.0c00210